luteolin 7-O-glucopyranoside

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: luteolin 7-O-glucopyranoside
• 英文别名: luteolin-7-O-glucoside；luteolin 7-glucoside；luteolin-7-glucoside；2-(3,4-Dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl-D-glucopyranoside；2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
• 化学式: C₂₁H₂₀O₁₁
• 分子量: 448.383
• InChiKey: PEFNSGRTCBGNAN-MKJMBMEGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  186
• 氢给体数：
  7
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  luteolin 7-O-glucopyranoside 生成 D-葡萄糖
  参考文献：
  名称：

  MANSOUR, R. M. A.;ABDALLA, M. F.;SALEH, N. A. M., BULL. CHEM. SOC. ETHIOPIA, 2,(1988) N 1, 45-46

  摘要：

  DOI：
• 作为产物：
  描述：

  在 palladium(II) hydroxide 、 环己烯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以52%的产率得到luteolin 7-O-glucopyranoside
  参考文献：
  名称：

  含葡萄糖的黄酮类化合物-它们的合成以及抗氧化和神经保护活性

  摘要：

  由于高反应性，活性氧可以攻击生物分子，从而导致细胞或组织损伤。在这项研究中，葡萄糖部分通过糖苷键或醚键连接在槲皮素3- O-甲基醚（1）和木犀草素（2）的C-7位。含葡萄糖的化合物在原代培养的大鼠皮层细胞中显示出有效的DPPH和超氧阴离子自由基清除和脂质过氧化抑制活性，并且对母体糖苷具有抗H 2 O 2诱导的氧化神经元损伤的几乎同等的保护作用。在测试的化合物中，3b和3c最有效（IC 50值分别为7.33和5.34μM），表现出与母体化合物1和2几乎相同的作用（IC 50分别 为3.50和3.75μM）。

  DOI：

  10.1016/j.bmcl.2009.09.062

文献信息

• [EN] COMPOUNDS EFFECTIVE IN TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES AND USES THEREOF<br/>[FR] COMPOSÉS EFFICACES POUR TRAITER L'HÉPATOTOXICITÉ ET DES STÉATOSES HÉPATIQUES, ET UTILISATIONS DE CEUX-CI
  申请人：SINEW PHARMA INC

  公开号：WO2017050298A1

  公开（公告）日：2017-03-30

  The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof.

  本发明涉及用于治疗肝毒性和脂肪肝疾病的化合物及其用途。
• Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus
  申请人：Lee-Huang Sylvia

  公开号：US20090061031A1

  公开（公告）日：2009-03-05

  The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

  本发明涉及一种治疗肥胖或肥胖相关疾病的方法和制药组合物，该方法适用于患有或易于发展肥胖或肥胖相关疾病的个体，或用于抑制HIV的感染，通过给予欧洲橄榄苦苷、其类似物或衍生物，或欧洲橄榄苦苷的主要代谢产物，包括欧洲橄榄苦苷去糖基体、羟基酪醇和环醇酸或其类似物、衍生物、一种虫草苷苷苷或一种secoiridoid苷苷苷或其类似物或衍生物，或上述任何组合，包括橄榄叶提取物。本发明还涉及通过测量从PPARγ2、LPL和αP2基因和基因产物选择的脂肪生成基因或其他脂肪生成、脂肪合成或脂解基因和基因产物的表达谱来筛选/诊断患有或易于患有肥胖或相关疾病的个体的方法。本发明还提供了筛选新欧洲橄榄苦苷类似物的方法。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ANTITUBERCULOSIS DRUGS
  申请人：Hu Oliver Yaopu

  公开号：US20140038921A1

  公开（公告）日：2014-02-06

  A pharmaceutical composition for treating tuberculotic diseases with no side effect/low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

  本发明提供了一种用于治疗结核病的药物组合物，该组合物不具有或具有较低的副作用。该组合物包含一种或多种化合物的药物有效量，所述化合物包括异烟肼、利福平、吡嗪酰胺和乙胺丁醇，以及一种或多种可以减少抗结核药物副作用的物质的药物有效量。
• Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus
  申请人：The General Hospital Corporation

  公开号：US20140296141A1

  公开（公告）日：2014-10-02

  The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

  本发明涉及使用欧洲橄榄苷、其类似物或衍生物，或欧洲橄榄苷的主要代谢产物，包括欧洲橄榄苷苷元、羟基酪醇和羟基酪醛酸或其类似物或衍生物、半萜苷苷元或半萜苷苷元类似物或衍生物，或上述任何组合物，包括橄榄叶提取物，用于治疗患有或易于发展肥胖症或肥胖相关疾病的受体，或用于抑制HIV的感染。本发明还涉及通过测量个体中PPARγ2、LPL和αP2基因和基因产物或其他脂肪生成、脂肪生成或脂肪分解基因和基因产物的表达谱来筛选/诊断患有或易于患有肥胖症或相关疾病的受体的方法。本发明还提供筛选新的欧洲橄榄苷类似物的方法。